Programme 2020

29th & 30th October 2020 Virtual Workshop

Thursday: October 29, 2020

10:00

(EST)

Introduction & Meeting Objectives      

John Gribben & David Maloney

10:05-11:25

Session I:  CAR-T in ALL

Chairs: Noelle Frey & Bijal Shah

  • Novel CAR-T approaches for ALL: Rebecca Gardner
  • CAR-T in adult ALL; Claire Roddie
  • Allogeneic CAR-T in ALL: Bijal Shah
  • Remission & Persistence: Shannon Maude

Panel discussion

11:25-12:45

Session 2: CAR-T in AML

Chairs: Saar Gill & John DiPersio

  • Overview: Saar Gill
  • CART vs BITE for AML: John DiPersio
  • NKG2D and anti-CD33 CART: David Sallman
  • CART-123 for AML: Elizabeth Budde

Panel discussion

12:45-14:00

Session 3: CAR-T in CLL

Chairs: John Gribben & David Porter

  • Update CLL CAR-T trial landscape/JCAR; Tanya Siddiqi
  • Long-term outcomes of anti-CD19 CAR-T in R/R CLL: David Porter
  • CAR NK treatments in CLL: Katy Rezvani
  • The role of CLL tumor cells in resistance to anti-CAR-T cell therapy: Joseph Melenhorst 

Panel Discussion

Day 1 Wrap up

Friday: October 30, 2020

10:00

Introduction from co-chairs John Gribben and David Maloney

10:00-11:15

Session 4:  CAR-T in Lymphoma

Chairs: Fred Locke and Caron Jacobson

  • CD19-CAR-T cells – trial updates: Jeremy Abramson
  • CD30 update: Barbara Savoldo
  • CD5 and CD7 CAR-T cells: Max Mamonkin

Panel Discussion

11:15-12:35

Session 5: CAR-T in Myeloma

Chairs: Yi Lin & Noopur Raje

  • BCMA CART – ready for standard of care practice?: Nina Shah
  • CART trials in China: myeloma and CART landscape in China: Jianxiang Wang
  • BITes vs CARs: Herman Einselle
  • Beyond BCMA, other novel CART targets and combinations: Eric Smith

Panel discussion

12:35-13:50

Session 6: Evolution of cellular therapies

Chairs: David Maloney

  • Tmod CAR T cells Targeting Loss of Heterozygosity: William Go
  • Repeat CAR T infusions (ALL, NHL and CLL): Jordan Gauthier
  • Informed design of engineered T cell therapies for cancer; Stan Riddell
  • New targets & technologies for CAR-T: Michael Hudecek

Panel discussion

Final Meeting Summary & Conclusions

© 2017 - 2020 World Health Communications Ltd / Brandcast Health

Media Partner:

Meeting Organizers: